Efficacy of dorzolamide-timolol combination as an adjunct to Intravitreal Bevacizumab in treatment of macular edema due to retinal vein occlusion

AIM -To study the effect of a topical aqueous suppressant in treatment of macular edema in branch retinal vein occlusion (BRVO).MATERIALS AND METHODS - In this study, two groups of 20 patients each with macular edema due to BRVO were randomized to receive IVB (2.5mg0.1ml) laser dorzolamide-timolol combination thrice daily (study group) or IVB laser (control group). Main outcome measures studied were visual acuity, reduction in central foveal thickness (CFT) and recurrence of macular edema. RESULTS -There was no significant difference between the 2 groups at 1 month but eyes in the control group had a significantly higher CFT at 6 months (p0.01) than study eyes. Visual acuity at 6 months was also better in study eyes than control eyes but this difference was not significant. CONCLUSION -Topical dorzolamide-timolol given thrice daily prolongs the effect of IVB thereby reducing the frequency of recurrence of macular edema in eyes with BRVO.